Viking Therapeutics, Inc. (NASDAQ: VKTX) has initiated a Phase 1 clinical trial of VK3019, an investigational dual amylin and calcitonin ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE